• Home
  • Pregnancy &           
Breastfeeding
  • Bookshop
  • Contact us
  • Donate now
  • Frequently Asked Questions
  • Please read

Our Helplines

1-877-439-2744 Motherisk Helpline
1-800-436-8477 Morning Sickness
1-877-327-4636 Alcohol and Substance
1-866-937-7678 Exercise in Pregnancy
1-888-246-5840 HIV and HIV Treatment
416-813-6780 Motherisk Helpline

The Cancer in Pregnancy Forum

Archived Questions and Answers
This Forum has been the centre of an exceptional exchange of knowledge diagnosis, treatment, symptoms and other effects of cancer during pregnancy and lactation. All are welcome to review the Questions and Answers posted here, provided that they acknowledge and accept the important proviso and disclaimer below.
Submit a question
Forum > Chemotherapy: Maternal
Methotrexate, azathioprine, mercaptopurine and cyclophosphamide

CCoPE
Date: 2001-12-14

Question:
My name is Dr. Judy Arnon, and I work in the Israeli Teratogen Information Service. We are now working on recommendations to the Israeli Ministry of Health concerning which women will be offered amniocentesis due to increased risk. One of the groups that are offered amniocentiesis (covered by the HMOs) are women (or their partners) that are exposed to methotrexate, azathioprine, mercaptopurine and cyclophosphamide prior to pregnancy. We are now reviewing this policy, and wanted to know if I could have information from your registry concerning exposure to these drugs and pregnancy outcome (especially in regard to chrosomal aberrations in the offspring). We are interested in both maternal and paternal exposure. Do you advise women (or their partners)who were exposed to these drugs 3-6 months prior to conception to do an amniocentesis? Thanking you in advance, Judy Arnon Ph.D., Israel Teratogen Information Service

Answer:
Offspring of patients, both male and female, treated with methotrexate, azathioprine, mercaptopurine and cyclophosphamide prior to pregnancy have not been found to have an increased risk of fetal malformation, over and above the baseline risk. As well, there is presently no evidence of increased chromosomal breakage in women or men taking these drugs.

Valid XHTML 1.0 Transitional [Valid RSS]

* - "MOTHERISK - Treating the mother - Protecting the unborn" is an official mark of The Hospital for Sick Children. All rights reserved.

The information on this website is not intended as a substitute for the advice and care of your doctor or other health-care provider. Always consult your doctor if you have any questions about exposures during pregnancy and before you take any medications.

Copyright © 1999-2013 The Hospital for Sick Children (SickKids). All rights reserved.

The Hospital for Sick Children (SickKids) is a health-care, teaching and research centre dedicated exclusively to children; affiliated with the University of Toronto. For general inquires please call: 416-813-1500.

  |  Contact SickKids  |  Terms of Use